105 related articles for article (PubMed ID: 8683863)
1. [Interleukin-3 therapy in patients with aplastic anemia refractory to prior therapies].
Miyairi Y; Murai K; Utsugisawa T; Narigasawa Y; Ito S; Shimosegawa K; Sugawara T; Numaoka H; Ono Y; Ito T; Ishida Y; Kuriya S
Rinsho Ketsueki; 1996 Jan; 37(1):22-8. PubMed ID: 8683863
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia.
Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S
Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579
[TBL] [Abstract][Full Text] [Related]
4. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia.
Raghavachar A; Ganser A; Freund M; Heimpel H; Herrmann F; Schrezenmeier H
Cytokines Mol Ther; 1996 Dec; 2(4):215-23. PubMed ID: 9384707
[TBL] [Abstract][Full Text] [Related]
5. [Two patients with aplastic anemia successfully treated with G-CSF and erythropoietin].
Hanamura A; Ichikawa A; Utsumi M; Hotta T
Rinsho Ketsueki; 1995 Dec; 36(12):1347-52. PubMed ID: 8587170
[TBL] [Abstract][Full Text] [Related]
6. [Sustained long-term complete remission in an elderly aplastic anemia patient after cessation of combined therapy consisting of granulocyte-colony stimulating factor and erythropoietin].
Yasuyama M; Kawauchi K; Sugiyama H; Ohkawa S
Rinsho Ketsueki; 2000 Jan; 41(1):42-7. PubMed ID: 10695398
[TBL] [Abstract][Full Text] [Related]
7. [A phase III trial of subcutaneous administration of rhG-CSF in aplastic anemia].
Yoshida Y; Okuma M; Suzuki T; Takahashi T; Nakagawa M; Kashima K; Abe T; Sonoda Y; Fujii H; Haruyama H
Rinsho Ketsueki; 1994 Nov; 35(11):1282-8. PubMed ID: 7529841
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia.
Takahashi M; Aoki A; Mito M; Nikkuni K; Ohtsuka T; Saitoh H; Moriyama Y; Shibata A
Hematol Pathol; 1993; 7(3):153-8. PubMed ID: 8244908
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
10. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
11. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
14. [Aplastic anemia successfully treated with erythropoietin and rhG-CSF].
Higashino K; Kito K; Hodohara K; Fujiyama Y; Banba T; Hosoda S
Rinsho Ketsueki; 1992 Sep; 33(9):1237-41. PubMed ID: 1279235
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
16. [RAEB in T with monosomy 7 after treatment of severe aplastic anemia with long term G-CSF].
Kaito K; Otsubo H; Ogasawara Y; Sekita T; Saeki A; Nishiwaki K; Masuoka H; Shimada T; Kobayashi M; Sakai O
Rinsho Ketsueki; 1995 Apr; 36(4):365-70. PubMed ID: 7540227
[TBL] [Abstract][Full Text] [Related]
17. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer.
Perillo A; Pierelli L; Battaglia A; Salerno MG; Rutella S; Cortesi E; Fattorossi A; De Rosa L; Ferraù F; Lalle M; Leone G; Mancuso S; Scambia G
Bone Marrow Transplant; 2002 Nov; 30(9):571-8. PubMed ID: 12407431
[TBL] [Abstract][Full Text] [Related]
18. [3-line response following long-term therapy of severe aplastic anemia using glycosylated rHuG-CSF: dysfunctional thrombocytes as early indication of a myelodysplastic syndrome].
Caspar CB; von Felten A; Widmer L; Burger J; Gmür J
Schweiz Med Wochenschr; 1994 Jan; 124(1-2):69-72. PubMed ID: 7507600
[TBL] [Abstract][Full Text] [Related]
19. Recovery of hematopoietic progenitor cells in patients with severe aplastic anemia who obtained good clinical response with a combination therapy of immunosuppressive agents and recombinant human granulocyte colony-stimulating factor.
Matsuo Y; Iwanaga M; Mori H; Yoshida S; Kawaguchi Y; Yakata Y; Murata K; Nagai K; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M
Int J Hematol; 2000 Jul; 72(1):37-43. PubMed ID: 10979207
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients.
Kolbe K; Peschel C; Rupilius B; Després D; Burger K; Sklenar I; Färber L; Huber C; Derigs HG
Bone Marrow Transplant; 1997 Dec; 20(12):1027-32. PubMed ID: 9466274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
